Jia Xin "Annie" Yu, Ph.D.

Data Scientist
New York | Email | (212) 688-7515 x231

Annie Yu is a data scientist for the CRI Clinical Accelerator and Venture Fund. She assists the Clinical Accelerator team in clinical trial due diligence, maintains the immuno-oncology landscape databases, and assists in bioinformatics projects. She contributes both a background in drug discovery and data science to further automate and standardize the databases and abilities of the Clinical Accelerator. She first joined the Cancer Research Institute in September 2018 as a research analyst for the Clinical Accelerator program.

Prior to joining CRI, Annie was awarded her Ph.D. in 2018 from the Graduate School of the Icahn School of Medicine at Mount Sinai for her dissertation work on discovering a new liver cancer target and drug scaffold with isoform selectivity. Her research was awarded the Predoctoral Fellowship (F31) from the National Cancer Institute. This work is awaiting publication in Molecular Cancer Therapeutics. Prior to graduate school, Annie graduated summa cum laude from Boston University with dual-degrees awarded (B.A. in Biochemistry and Molecular Biology; M.A. in Biotechnology). Annie also worked as a research technician studying immunoglobulin recombination at SUNY Downstate.

While in graduate school, Annie also earned a certificate from the DREAM Challenges Academy for her work on the NCI-CPTAC DREAM Proteogenomics Computational Challenge in 2017, where she became adept at SQL, Python, and R. She believes in using big data to improve biomedical sciences at all levels, including immuno-oncology.

Select publications: 

  • Yu JX, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Trends in clinical development for PD-1/PD-L1 inhibitors. Nature Reviews Drug Discovery. 2019 November. (DOI: 10.1038/d41573-019-00182-w)
  • Yu JX, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nature Reviews Drug Discovery. 2019 September. (DOI: 10.1038/d41573-019-00167-9)
  • Yu JX, Hubbard-Lucey VM, Tang J. The global pipeline of cell therapies for cancer. Nature Reviews Drug Discovery. 2019 May. (PMID: 31673124)
  • Yu JX, Craig AJ, Duffy ME, Villacorta-Martin C, Miguela V, Ruiz de Galarreta M, Scopton AP, Silber L, Maldonado AY, Rialdi A, Guccione E, Lujambio A, Villanueva A, Dar AC. Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as therapeutic targets in HCC. Molecular Cancer Therapeutics. 2019 June. (PMID: 31213506)
  • Piacentino ML, Zuch DT, Fishman J, Rose S, Speranza EE, Li C, Yu J, Chung O, Ramachandran J, Ferrell P, Patel V, Reyna A, Hameeduddin H, Chaves J, Hewitt FB, Bardot E, Lee D, Core AB, Hogan JD, Keenan JL, Luo L, Coulombe-Huntington J, Blute TA, Oleinik E, Ibn-Salem J, Poustka AJ, Bradham CA. RNA-Seq identifies SPGs as a ventral skeletal patterning cue in sea urchins. Development. 2016 Jan. (PMID: 26755701)
  • Piacentino ML, Chung O, Ramachandran J, Zuch DT, Yu J, Conaway EA, Reyna AE, Bradham CA. Zygotic LvBMP5-8 is required for skeletal patterning and for left-right but not dorsal-ventral specification in the sea urchin embryo. Dev Biology. 2016 Apr. (PMID: 26905309)

Changing the Way Cancer is Treated and Cured

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.